With GLP-1 drugs gaining widespread popularity, the coming years will see unprecedented attention directed toward obesity drug development. This momentum presents a new challenge: next-generation therapeutics—amylin analogues, multi-target agonists, and gene and nucleic acid therapies—are far more complex in their mechanisms, and traditional preclinical platforms will likely struggle to deliver the predictive accuracy needed to guide developers through the challenges ahead.
Given the high stakes, pharmaceutical companies and research institutions will need to pay special attention to optimizing the selection of obesity models based on mechanism of action, with the aim of improving R&D efficiency and clinical translation success rates. Traditional DIO (diet-induced obesity) models carry inherent limitations, focusing heavily on macroscopic endpoints—particularly changes in body weight and food intake—while overlooking critical pharmacodynamic dimensions: body composition, energy metabolic homeostasis, dynamic changes in insulin sensitivity, and target organ histopathology. This likely contributes to the high attrition rate of compounds that perform well in preclinical studies but are ultimately abandoned in clinical trials due to efficacy or safety concerns.
The maturation of CRISPR/Cas9 gene editing technology is reshaping model development. Gene editing-based obesity models now enable precise recapitulation of human obesity-associated genetic mutations (LEP, LEPR, MC4R pathways), providing previously unavailable validation platforms—with humanized models supporting antibody target validation and conventional knockout/knock-in models enabling mechanistic studies of target biology. The model selection paradigm has evolved from "availability" to "precision matching."
To address the diverse requirements across different development stages and target types, Protheragen Obesity has established a tiered, customizable obesity models technical system: In vitro cell models including 3T3-L1 preadipocyte differentiation system and primary adipocyte and hepatocyte co-culture platforms supporting high-throughput screening; gene-edited models such as single/multi-gene mutations, transgenic, and humanized replacement models suitable for antibody and gene therapy vector validation; diet-induced models including high-fat, high-sugar, and high-fat combined with low-dose STZ for obesity with type 2 diabetes comorbidities; and chemically induced and surgically induced models such as hypothalamic injury models and ovariectomy models addressing specific mechanistic questions. Each model is equipped with a comprehensive metabolic phenotyping system covering DEXA/MRI body composition monitoring, indirect calorimetry, glucose and insulin tolerance testing, and histopathological examination.
Protheragen Obesity operates under a GLP-compliant quality management system. For DIO studies—which typically run 8 to 16 weeks—the model induction success rate exceeds 90%. For gene-edited models, they provide comprehensive genotyping reports, copy number and integration site analysis, and germline transmission validation data. All study reports meet FDA and NMPA requirements for IND-enabling pharmacology submissions. The company offers three collaboration models: full-service outsourcing, modular services, and co-development partnerships, with every engagement beginning with a consultation phase where the technical team works directly with client researchers to understand the molecular modality, mechanism of action, and regulatory pathway, then customizes the optimal model strategy.
